Seu efeito diurtico ajuda a reduzir o excesso de lquido no corpo, contribuindo para a perda de peso e ajudando na reduo do inchao corporal
In-depth exploration of these pathways and their interactions is of great significance for identifying new clinical treatment targets

Genetic variability in the receptors for GLP-1 (GLP-1R rs10305420, GLP-1R rs6923761) and GIP (GIPR rs1800437) has been associated with increased odds of AD and PD while correlating with elevated disease biomarkers (ie, amyloid-beta (A) peptide 42, tau proteins clustered in neurofibrillary tangles (NFT)) measured in the cerebrospinal fluid (CSF).19 A Mendelian randomisation study from the UK Biobank data found an association between genetic variants coding for GLP-1RAs and a lower risk of ADalthough these results must be interpreted cautiously as the study failed to show the expected associations with weight loss used as a positive control.18 Low levels of GLP-1 in serum were suggestive of higher odds of mild cognitive impairment (MCI) in a small sample of 106 patients with T2DM.21 More recently, a major study on the effects of the GLP-1RA semaglutide on the circulating proteome of some 2000 participants with overweight or obesity plus or minus diabetes from two phase III trials (STEP 1 and STEP 2) has identified two significantly regulated proteins, namely tenascin-C and progranulin, that are implicated in AD neuropathology.20 From a mechanistic perspective, however, most evidence regarding the putative neuroprotective activity of GLP-1RAs stems from preclinical, that is, in vitro or animal models.10 17 In summary, beyond peripheral glycaemic control, GLP-1RAs display broad actions against neurodegeneration and ageing processes while being capable of enhancing cognitive abilities

Frequently Asked Questions About GLP-1 Signaling How can I increase GLP-1 signaling naturally